Potential biomarkers for head and neck squamous cell carcinoma

Jimmy J Brown, Helen Xu, Junko Nishitani, Hezla Mohammed, Ryan Osborne, Senait Teklehaimanot, Gus Gill, Xuan Liu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: The purpose of the study was twofold: 1) to search for potential biomarkers that were overexpressed in cell lines that could represent both a clinical premalignant (immortalized) and a malignant state, and 2) to attempt to correlate metallothionein gene expression with clinical outcome in laryngeal carcinoma. Study Design: A series of in vitro experiments were used to unearth differentially expressed genes among normal, immortalized and tumorigenic cell lines. Secondarily, a retrospective analysis was undertaken. Methods: Differential display analysis was conducted to identify differentially expressed genes between human papillomavirus-infected immortalized HOK16B and benzo[α]pyrene-derived tumorigenic cell line, HOK16B-BaP-T. The cell-specific expressions were examined by Northern blot analysis and compared with other known immortalized and cancer cell lines. Immunohistochemical staining was also conducted to localize metallothionein (MT I/II) protein expression among the different cell lines studied. A retrospective analysis of laryngeal specimens from archival tissues of 29 cancer patients who underwent primary surgical resection was also undertaken after immunohistochemical staining. Results: Twenty-one differentially expressed complementary cDNA clones, both novel and known, were identified using the differential display analysis. Northern blot analysis confirmed that clone 6 hybridized to a 1.6-kb RNA in HOK16B-Bap-T cell line. Clone 4 showed decreased expression in immortalized and cancer cell compared with NHOK. MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. Conclusion: These findings suggest that clone 4 may potentially function as a tumor suppressor gene, which may be significant in tumor progression and invasion. Clone 6 may participate in viral-mediated oncogenic transformation of normal cells. Clone 6 may also have potential as a tumor maker differentiating normal from malignant tissue, as in the determination of surgical resection margins. MT I/II gene product may serve as a prognostic biomarker for laryngeal squamous cell carcinoma. The differentially expressed genes and gene products may serve as sensitive biomarkers for improved early detection, diagnosis, and prognosis of head and neck squamous cell carcinoma.

Original languageEnglish (US)
Pages (from-to)393-400
Number of pages8
JournalLaryngoscope
Volume113
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Clone Cells
Biomarkers
Cell Line
Metallothionein
Genes
Neoplasms
Northern Blotting
Staining and Labeling
Laryngeal Neoplasms
Tumor Suppressor Genes
Carcinoma, squamous cell of head and neck
Early Diagnosis
Squamous Cell Carcinoma
Complementary DNA
RNA
Carcinoma
T-Lymphocytes
Gene Expression
Recurrence
Proteins

Keywords

  • Biomarkers
  • Head and neck squamous cell carcinoma
  • Immortalized
  • Metallothionein
  • Premalignant

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Brown, J. J., Xu, H., Nishitani, J., Mohammed, H., Osborne, R., Teklehaimanot, S., ... Liu, X. (2003). Potential biomarkers for head and neck squamous cell carcinoma. Laryngoscope, 113(3), 393-400. https://doi.org/10.1097/00005537-200303000-00001

Potential biomarkers for head and neck squamous cell carcinoma. / Brown, Jimmy J; Xu, Helen; Nishitani, Junko; Mohammed, Hezla; Osborne, Ryan; Teklehaimanot, Senait; Gill, Gus; Liu, Xuan.

In: Laryngoscope, Vol. 113, No. 3, 01.03.2003, p. 393-400.

Research output: Contribution to journalArticle

Brown, JJ, Xu, H, Nishitani, J, Mohammed, H, Osborne, R, Teklehaimanot, S, Gill, G & Liu, X 2003, 'Potential biomarkers for head and neck squamous cell carcinoma', Laryngoscope, vol. 113, no. 3, pp. 393-400. https://doi.org/10.1097/00005537-200303000-00001
Brown JJ, Xu H, Nishitani J, Mohammed H, Osborne R, Teklehaimanot S et al. Potential biomarkers for head and neck squamous cell carcinoma. Laryngoscope. 2003 Mar 1;113(3):393-400. https://doi.org/10.1097/00005537-200303000-00001
Brown, Jimmy J ; Xu, Helen ; Nishitani, Junko ; Mohammed, Hezla ; Osborne, Ryan ; Teklehaimanot, Senait ; Gill, Gus ; Liu, Xuan. / Potential biomarkers for head and neck squamous cell carcinoma. In: Laryngoscope. 2003 ; Vol. 113, No. 3. pp. 393-400.
@article{a08b6412fbc64a4cb20a1dd0f6df9195,
title = "Potential biomarkers for head and neck squamous cell carcinoma",
abstract = "Objective: The purpose of the study was twofold: 1) to search for potential biomarkers that were overexpressed in cell lines that could represent both a clinical premalignant (immortalized) and a malignant state, and 2) to attempt to correlate metallothionein gene expression with clinical outcome in laryngeal carcinoma. Study Design: A series of in vitro experiments were used to unearth differentially expressed genes among normal, immortalized and tumorigenic cell lines. Secondarily, a retrospective analysis was undertaken. Methods: Differential display analysis was conducted to identify differentially expressed genes between human papillomavirus-infected immortalized HOK16B and benzo[α]pyrene-derived tumorigenic cell line, HOK16B-BaP-T. The cell-specific expressions were examined by Northern blot analysis and compared with other known immortalized and cancer cell lines. Immunohistochemical staining was also conducted to localize metallothionein (MT I/II) protein expression among the different cell lines studied. A retrospective analysis of laryngeal specimens from archival tissues of 29 cancer patients who underwent primary surgical resection was also undertaken after immunohistochemical staining. Results: Twenty-one differentially expressed complementary cDNA clones, both novel and known, were identified using the differential display analysis. Northern blot analysis confirmed that clone 6 hybridized to a 1.6-kb RNA in HOK16B-Bap-T cell line. Clone 4 showed decreased expression in immortalized and cancer cell compared with NHOK. MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. Conclusion: These findings suggest that clone 4 may potentially function as a tumor suppressor gene, which may be significant in tumor progression and invasion. Clone 6 may participate in viral-mediated oncogenic transformation of normal cells. Clone 6 may also have potential as a tumor maker differentiating normal from malignant tissue, as in the determination of surgical resection margins. MT I/II gene product may serve as a prognostic biomarker for laryngeal squamous cell carcinoma. The differentially expressed genes and gene products may serve as sensitive biomarkers for improved early detection, diagnosis, and prognosis of head and neck squamous cell carcinoma.",
keywords = "Biomarkers, Head and neck squamous cell carcinoma, Immortalized, Metallothionein, Premalignant",
author = "Brown, {Jimmy J} and Helen Xu and Junko Nishitani and Hezla Mohammed and Ryan Osborne and Senait Teklehaimanot and Gus Gill and Xuan Liu",
year = "2003",
month = "3",
day = "1",
doi = "10.1097/00005537-200303000-00001",
language = "English (US)",
volume = "113",
pages = "393--400",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Potential biomarkers for head and neck squamous cell carcinoma

AU - Brown, Jimmy J

AU - Xu, Helen

AU - Nishitani, Junko

AU - Mohammed, Hezla

AU - Osborne, Ryan

AU - Teklehaimanot, Senait

AU - Gill, Gus

AU - Liu, Xuan

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Objective: The purpose of the study was twofold: 1) to search for potential biomarkers that were overexpressed in cell lines that could represent both a clinical premalignant (immortalized) and a malignant state, and 2) to attempt to correlate metallothionein gene expression with clinical outcome in laryngeal carcinoma. Study Design: A series of in vitro experiments were used to unearth differentially expressed genes among normal, immortalized and tumorigenic cell lines. Secondarily, a retrospective analysis was undertaken. Methods: Differential display analysis was conducted to identify differentially expressed genes between human papillomavirus-infected immortalized HOK16B and benzo[α]pyrene-derived tumorigenic cell line, HOK16B-BaP-T. The cell-specific expressions were examined by Northern blot analysis and compared with other known immortalized and cancer cell lines. Immunohistochemical staining was also conducted to localize metallothionein (MT I/II) protein expression among the different cell lines studied. A retrospective analysis of laryngeal specimens from archival tissues of 29 cancer patients who underwent primary surgical resection was also undertaken after immunohistochemical staining. Results: Twenty-one differentially expressed complementary cDNA clones, both novel and known, were identified using the differential display analysis. Northern blot analysis confirmed that clone 6 hybridized to a 1.6-kb RNA in HOK16B-Bap-T cell line. Clone 4 showed decreased expression in immortalized and cancer cell compared with NHOK. MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. Conclusion: These findings suggest that clone 4 may potentially function as a tumor suppressor gene, which may be significant in tumor progression and invasion. Clone 6 may participate in viral-mediated oncogenic transformation of normal cells. Clone 6 may also have potential as a tumor maker differentiating normal from malignant tissue, as in the determination of surgical resection margins. MT I/II gene product may serve as a prognostic biomarker for laryngeal squamous cell carcinoma. The differentially expressed genes and gene products may serve as sensitive biomarkers for improved early detection, diagnosis, and prognosis of head and neck squamous cell carcinoma.

AB - Objective: The purpose of the study was twofold: 1) to search for potential biomarkers that were overexpressed in cell lines that could represent both a clinical premalignant (immortalized) and a malignant state, and 2) to attempt to correlate metallothionein gene expression with clinical outcome in laryngeal carcinoma. Study Design: A series of in vitro experiments were used to unearth differentially expressed genes among normal, immortalized and tumorigenic cell lines. Secondarily, a retrospective analysis was undertaken. Methods: Differential display analysis was conducted to identify differentially expressed genes between human papillomavirus-infected immortalized HOK16B and benzo[α]pyrene-derived tumorigenic cell line, HOK16B-BaP-T. The cell-specific expressions were examined by Northern blot analysis and compared with other known immortalized and cancer cell lines. Immunohistochemical staining was also conducted to localize metallothionein (MT I/II) protein expression among the different cell lines studied. A retrospective analysis of laryngeal specimens from archival tissues of 29 cancer patients who underwent primary surgical resection was also undertaken after immunohistochemical staining. Results: Twenty-one differentially expressed complementary cDNA clones, both novel and known, were identified using the differential display analysis. Northern blot analysis confirmed that clone 6 hybridized to a 1.6-kb RNA in HOK16B-Bap-T cell line. Clone 4 showed decreased expression in immortalized and cancer cell compared with NHOK. MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. Conclusion: These findings suggest that clone 4 may potentially function as a tumor suppressor gene, which may be significant in tumor progression and invasion. Clone 6 may participate in viral-mediated oncogenic transformation of normal cells. Clone 6 may also have potential as a tumor maker differentiating normal from malignant tissue, as in the determination of surgical resection margins. MT I/II gene product may serve as a prognostic biomarker for laryngeal squamous cell carcinoma. The differentially expressed genes and gene products may serve as sensitive biomarkers for improved early detection, diagnosis, and prognosis of head and neck squamous cell carcinoma.

KW - Biomarkers

KW - Head and neck squamous cell carcinoma

KW - Immortalized

KW - Metallothionein

KW - Premalignant

UR - http://www.scopus.com/inward/record.url?scp=0037334813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037334813&partnerID=8YFLogxK

U2 - 10.1097/00005537-200303000-00001

DO - 10.1097/00005537-200303000-00001

M3 - Article

C2 - 12616185

AN - SCOPUS:0037334813

VL - 113

SP - 393

EP - 400

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 3

ER -